Loading...
XSTOKAN
Market cap12mUSD
Dec 23, Last price  
1.16SEK
1D
0.00%
1Q
-40.82%
Jan 2017
-95.26%
IPO
-97.17%
Name

Kancera AB

Chart & Performance

D1W1MN
XSTO:KAN chart
P/E
—
P/S
135.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
30.15%
Rev. gr., 5y
23.65%
Revenues
1m
+37.45%
07,069,0003,839,0001,813,000470,000282,000308,000113,000358,0003,216,00090,0001,704,000753,0001,035,000
Net income
-65m
L+23.64%
-7,147,000-18,410,000-33,488,000-7,418,000-15,979,000-19,612,000-22,308,000-56,198,000-45,935,000-36,095,000-47,558,000-45,686,000-52,484,000-64,888,999
CFO
-56m
L+17.05%
-5,644,000-23,214,000-27,081,000-6,638,000-19,105,000-20,658,000-23,103,000-53,541,000-45,043,000-33,286,000-46,046,000-44,125,000-47,562,000-55,672,000
Earnings
Feb 21, 2025

Profile

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
URL
https://kancera.com/
IPO date
Feb 21, 2011
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,035
37.45%
753
-55.81%
1,704
1,793.33%
Cost of revenue
66,077
53,047
47,280
Unusual Expense (Income)
NOPBT
(65,042)
(52,294)
(45,576)
NOPBT Margin
Operating Taxes
(432)
(413)
Tax Rate
NOPAT
(65,042)
(51,862)
(45,163)
Net income
(64,889)
23.64%
(52,484)
14.88%
(45,686)
-3.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,215
36,759
95,940
BB yield
-1.73%
-28.99%
-23.38%
Debt
Debt current
(2,174)
125
Long-term debt
1,009
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(45,693)
(97,324)
(105,388)
Cash flow
Cash from operating activities
(55,672)
(47,562)
(44,125)
CAPEX
Cash from investing activities
Cash from financing activities
6,215
36,190
95,638
FCF
(64,795)
(51,502)
(44,843)
Balance
Cash
45,692
95,149
106,521
Long term investments
1,000
1,000
1,000
Excess cash
45,641
95,112
106,437
Stockholders' equity
(357,908)
(294,668)
(261,671)
Invested Capital
405,573
399,405
384,774
ROIC
ROCE
EV
Common stock shares outstanding
81,503
59,534
66,941
Price
4.42
107.51%
2.13
-65.25%
6.13
-61.98%
Market cap
360,245
184.09%
126,807
-69.10%
410,348
-42.09%
EV
314,552
29,483
567,733
EBITDA
(62,042)
(51,934)
(45,256)
EV/EBITDA
Interest
118
17
Interest/NOPBT